EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy

Qishan Wang, Zhihao Wu, Yuanqin Yang, Chao Yang, Haoran Deng, Xingyue Zhou, Shuting Xu, Lingling Wu, Xiaochuan Hong, Xueni Yu, Lu Lu, Liufu Deng

Cell Reports · 2025-10 · 44 (10) · 116314

DOI: 10.1016/j.celrep.2025.116314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025-10. Verfasst von Qishan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceuti…. Hauptthemen laut MEDLINE: Epigenesis, Genetic, RNA-Binding Proteins, Erb-b2 Receptor Tyrosine Kinases, DNA-Binding Proteins. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Jiao Tong University, Science and Technology Commission of Shanghai Municipality, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epigenesis, GeneticRNA-Binding ProteinsErb-b2 Receptor Tyrosine KinasesDNA-Binding ProteinsNeoplasmsHumansAnimalsCell Line, TumorMiceDecitabineSignal TransductionCD8-Positive T-LymphocytesFemaleImmunotherapyMice, Inbred BALB C

Stichwörter der Autor:innen

CD8(+) T cell responsesCP: CancerHER2-targeted therapyZBP1 pathwayepigenetic therapytumor immunogenicity

Substanzen

RNA-Binding ProteinsErb-b2 Receptor Tyrosine KinasesDNA-Binding ProteinsDecitabine

Autor:innen und Institutionen

  • Shanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Shanghai Frontiers Science Center of Drug Target Identification and Delivery, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China. E…

Förderung

  • Shanghai Jiao Tong University
  • Science and Technology Commission of Shanghai Municipality
  • Fundamental Research Funds for the Central Universities
  • Recruitment Program of Global Experts
  • National Natural Science Foundation of China

Zitieren

APA

Wang, Q., Wu, Z., Yang, Y., Yang, C., Deng, H., Zhou, X., Xu, S., Wu, L., Hong, X., Yu, X., Lu, L., & Deng, L. (2025). ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy. Cell Reports, 44(10), 116314. https://doi.org/10.1016/j.celrep.2025.116314

Vancouver

Wang Q, Wu Z, Yang Y, Yang C, Deng H, Zhou X, et al. ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy. Cell Reports. 2025;44(10):116314. doi:10.1016/j.celrep.2025.116314

BibTeX
@article{Wang2025,
  author = {Wang, Qishan and Wu, Zhihao and Yang, Yuanqin and Yang, Chao and Deng, Haoran and Zhou, Xingyue and Xu, Shuting and Wu, Lingling and Hong, Xiaochuan and Yu, Xueni and Lu, Lu and Deng, Liufu},
  title = {ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy},
  journal = {Cell Reports},
  year = {2025},
  volume = {44},
  number = {10},
  pages = {116314},
  doi = {10.1016/j.celrep.2025.116314}
}
Kostenlos starten →